Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

• Main Authors: Hisanori Shimizu (Author), Kenichi Suzuki (Author), Takeshi Uchikura (Author), Daiki Tsuji (Author), Takeharu Yamanaka (Author), Hironobu Hashimoto (Author), Koichi Goto (Author), Reiko Matsui (Author), Nobuhiko Seki (Author), Toshikazu Shimada (Author), Shunya Ikeda (Author), Naoki Ikegami (Author), Toshihiro Hama (Author), Nobuyuki Yamamoto (Author), Tadanori Sasaki (Author)
• Format: Book
• Published: BMC, 2018-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant and dexamethasone in preventing chemotherapy-induc...